Is Teva Pharmaceutical Industries Limited (TEVA) Stock Undervalued After Recent Pullback and Vitiligo Program Update?

We recently compiled a list of the 12 Best Low-Priced Pharma Stocks to Buy Right Now. Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the best low-priced pharma stocks on this list.

TheFly reported on June 18 that Jefferies analyst Dennis Ding maintained a Buy rating and a $40 price target on TEVA following recent share weakness. The analyst noted that the decline was largely influenced by broader market factors and investor reactions to management comments regarding the company’s vitiligo program, along with a clinical trial update shifting the expected primary completion date. After discussions with Teva’s investor relations team, confidence in the vitiligo program remained unchanged, with data still expected shortly after the July 4 weekend. Jefferies continues to view the recent pullback as an opportunity and remains positive on the shares.

Is Teva Pharmaceutical Industries Limited (TEVA) Stock Undervalued After Recent Pullback and Vitiligo Program Update?

Separately, on June 5, Teva Pharmaceutical Industries Limited (NYSE:TEVA) announced new real-world findings from a decentralized study examining the impact of Huntington’s disease chorea on patients and caregivers, along with the effects of AUSTEDO and AUSTEDO XR on symptom management. The data showed that treatment was associated with improvements in chorea symptoms and multiple quality-of-life areas. Presented at the Advanced Therapeutics in Movement & Related Disorders Congress, the study found that 74% of patients reported improved movements after starting therapy. Additionally, more than 85% of patients noted progress toward daily activity and social goals, while 77% of caregivers reported improvements in social and emotional well-being measures.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) is the world’s largest generic drug manufacturer, providing affordable medicines and specialty therapies across nearly 60 markets with a global healthcare presence.

While we acknowledge the risk and potential of TEVA  as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than TEVA and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1